Abstract:Background The long-term safety and efficacy of drug-eluting stents (DES) versus bare metal stents (BMS) are unclear and controversial issues in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES versus BMS implantation.Methods A total of 191 patients with acute STEMI undergoing PCI from Jan. 2005 to Dec. 2007 were enrolled. Patients received DES (n=83) or BMS (n=108) implantation in the infarction related artery according to physician's discretion. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of death, myocardial infarction (MI), target vessel revascularization (TVR) and stent thrombosis. The difference of MACE was observed between DES and BMS groups.Results The clinical follow-up duration was 3 years ((41.7 +/- 16.1) months). MACE occurred in 20 patients during three years follow-up. Logistic regression analysis showed that the left ventricular ejection fraction (LVEF) was an independent predictor for MACE in the follow-up period (P=0.0301). There was no significant difference in all-cause mortality (3.61% vs. 7.41%, P=0.2647), the incidence of myocardial infarction (0 vs. 0.93%, P=0.379) and stent thrombosis (1.20% vs. 1.85%, P=0.727) between the DES group and BMS group. The incidence of MACE was significantly lower in the DES group compared to the BMS group (4.82% vs. 14.81%, P=0.0253). The rate of TVR was also lower in the DES group (0 vs. 5.56%, P=0.029). In the DES group, there was no significant difference in the incidence of MACE between sirolimus eluting stents (SES, n=73) and paclitaxel-eluting stents (PES, n=10) subgroups (2.74% vs. 20.00%, P>0.05).Conclusions This finding suggested that drug-eluting stents significantly reduced the need for revascularization in patients with acute STEMI, without increasing the incidence of death or myocardial infarction. Use of DES significantly decreased the incidence of MACE compared with BMS during the 3-year follow-up. Chin Med J 2012;125(16):2803-2806

The clinical safety and short-term therapeutic efficacy of EXCEL drug-eluting stent

Safety and Efficacy of the Cypher Select Sirolimus-Eluting Stent in the "real World" - Clinical and Angiographic Results from the China Cypher Select Registry

Long‐term Clinical, Angiographic, and Intravascular Ultrasound Outcomes of Biodegradable Polymer‐coated Sirolimus‐eluting Stents

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.

[The Safety and Efficacy of Cypher Drug-Eluting Stent: Results from a Six Months Follow-Up Study in Patients with ST-segment Elevation Myocardial Infarction].

Efficacy and Safety of a Biodegradable Polymer Cobalt-Chromium Sirolimus-Eluting Stent (EXCEL2) in Treating De Novo Coronary Artery Disease: A Pooled Analysis of the CREDIT II and CREDIT III Trials. DOI: 10.1002/ccd.26887

First‐in‐man Study Evaluating the Safety and Efficacy of a Second Generation Biodegradable Polymer Sirolimus‐eluting Stent in the Treatment of Patients with De Novo Coronary Lesions: Clinical, Angiographic, and OCT Outcomes of CREDIT‐1

The application of cypherTM drug-eluting stent in patient with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention

A study of treatment with different drug eluting stents in coronary heart disease

Safety And Efficacy Of Biodegradable-Polymer Coated Sirolimus-Eluting Stents In Real-World Practice: 18-Month Clinical And 9-Month Angiographic Outcomes

Clinical Follow-Up Observation of Drug-Eluting Stent in Treatment of Acute Myocardial Infarction

The Application of CypherTM Drug-Eluting Stent in Patient with Unstable Angina Treated by Percutaneous Coronary Intervention

A New Generation of Biodegradable Polymer-Coated Sirolimus-Eluting Stents for the Treatment of Coronary Artery Disease: Final 5-Year Clinical Outcomes from the CREATE Study.

Efficacy and Safety of A Second Generation Biodegradable-Polymer Sirolimus-Eluting Stent: One Year Results of The CREDIT 2 Trial.

Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Safety and efficacy of the second generation biodegradable polymer Cobalt-Chromium sirolimus-eluting stent (EXCEL 2) stent in diabetic patients:A Subgroup analysis of the CREDIT Ⅱ and CREDIT Ⅲ trials

Comparison of Long-Term Safety of Coronary Sirolimus-Eluting Stent with Bare Metal Stent Implantation in Patients with Multivessel Coronary Disease

Short and Intermediate Term Clinical Outcome of Sirolimus-Eluting Stent Implantation in Patients with ST-segment Elevation Myocardial Infarction

Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.